We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Promise and Perils of ‘Targeted Therapy’ of Advanced Ovarian Cancer.
- Authors
Markman, Maurie
- Abstract
For several reasons, ovarian cancer is an excellent malignancy to consider the use of ‘targeted’ therapeutic strategies. However, to date, despite considerable effort, there remains limited evidence that such approaches are clinically relevant in the malignancy. The one important exception is the delivery of anti-angiogenic anti-neoplastic agents, which actually appear to be more biologically active as single drugs in ovarian cancer than in other solid tumors where they have been examined. It is anticipated that future trials of ‘targeted’ therapy in ovarian cancer will focus on molecular targets of documented relevance in the malignancy. Copyright © 2008 S. Karger AG, Basel
- Subjects
OVARIAN cancer; BEVACIZUMAB; EPIDERMAL growth factor; PROTEIN-tyrosine kinase inhibitors; ANTINEOPLASTIC agents
- Publication
Oncology, 2008, Vol 74, Issue 1/2, p1
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000138349